BCN HEALTH presents a systematic review evaluating the cost-effectiveness of tumor-infiltrating lymphocyte therapy (TIL-ACT) with HD-IL-2
BCN HEALTH presented the study “Economic evaluation of TIL-ACT with HD-IL-2: a systematic literature review of costs and cost-effectiveness” on June 19 in Madrid during the Annual Conference of the Spanish Health Economics Association (AES).
The study, led by researchers from BCN HEALTH and the Vall d’Hebron Institute of Oncology (VHIO), analyzes the economic burden of tumor-infiltrating lymphocyte adoptive cell therapy (TIL-ACT) combined with high-dose interleukin-2 (HD-IL-2), focusing on healthcare resource use, treatment costs, and cost-effectiveness in melanoma, non-small cell lung cancer (NSCLC), and cervical cancer.
A systematic literature review was conducted in accordance with PRISMA guidelines, identifying five relevant studies out of more than 600 references. Total per-patient costs ranged from €69,745 to €292,369 depending on treatment settings, production volume, and methodology. TIL manufacturing was the costliest component (€35,500–€67,547), followed by hospital admission and follow-up (€26,500–€47,908).
Findings show that TIL-ACT is a cost-effective option compared to ipilimumab in advanced melanoma in countries such as the Netherlands and Denmark, being dominant or within acceptable willingness-to-pay thresholds of up to €80,000 per QALY. However, no economic data were found for NSCLC or cervical cancer, highlighting the need for further studies to support broader adoption across different tumor types and healthcare systems.
This study is part of the PragmaTIL project, funded by the European Union under the Horizon Europe programme grant agreement no. 101104684.